AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) traded up 4.1% during trading on Thursday . The stock traded as high as $4.7491 and last traded at $4.55. 82,457 shares were traded during trading, an increase of 426% from the average session volume of 15,685 shares. The stock had previously closed at $4.37.
AlloVir Trading Up 3.7%
The stock has a market cap of $23.80 million, a P/E ratio of -0.23 and a beta of 0.63. The company’s 50 day moving average price is $5.22 and its two-hundred day moving average price is $7.37.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Read More
- Five stocks we like better than AlloVir
- MarketBeat Week in Review – 06/15 – 06/19
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
